Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P160042/S032

Revanesse Versa, Revanesse Versa+ (with lidocaine) and Revanesse Lips+ (with lidocaine)

Prollenium Medical Technologies, Inc. · Decision date Oct 14, 2026

MEDTECHLEDGER EXPLANATIONP160042/S032

What did the FDA decide?

The FDA record for P160042/S032 describes a 30-day notice submitted by Prollenium Medical Technologies, Inc. Its stated purpose is approval to qualify a third-party logistics (3PL) supplier for warehousing and temperature-controlled storage of Revanesse Versa, Revanesse Versa+, and Revanesse Lips+ finished products. The supplement reason is listed as a process change covering manufacturer, sterilizer, packager or supplier.

The S032 identifier places this as a supplement to PMA P160042; it is not a new approval of the whole device system, and the notice concerns a supplier and storage arrangement rather than a clinical claim. The record does not identify the 3PL supplier, the storage site, temperature ranges, or any safety or effectiveness data, so the reported purpose should be read as the applicant's stated scope, not as independent evidence of product performance.

The device category is an implant, dermal, for aesthetic use, with product code LMH.

FDA approval order statement

Approval to qualify a Third-Party Logistics (3PL) supplier for warehousing and temperature-controlled storage of Revanesse Versa, Revanesse Versa+, and Revanesse Lips+ finished products
Regulatory pathway
PMA supplement
Supplement type
30-Day Notice
Clinical specialty
General, Plastic Surgery
Decision date
Oct 14, 2026
FDA change category
Process Change - Manufacturer/Sterilizer/Packager/Supplier

FDA source record · MedtechLedger’s explanation describes the recorded change.

Regulatory record facts

Identifier
P160042/S032
Regulatory pathway
PMA supplement
Product code
LMH
Decision code
OK30
Decision date
Oct 14, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Implant, dermal, for aesthetic use.

Product code
LMH
FDA device class
3

For the original device and its historical approval scope, see PMA P160042. Subsequent supplements may change the device or its indications.

FDA decision timeline

  1. P160042/S032 received

    Application receipt date recorded by FDA.

  2. P160042/S032 · FDA decision

    30-Day Notice

Timeline entries are records held by MedtechLedger for P160042. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P160042

Product / regulatory recordCompanyPathwayDecision dateSource
Prollenium Medical Technologies, Inc.PMA approvalAug 4, 2017FDA

Explore the linked device profile

Other records with product code LMH

Product / regulatory recordCompanyPathwayDecision dateSource
AllerganPMA supplementNov 4, 2026FDA
Merz North America, Inc.PMA supplementNov 4, 2026FDA
Merz North America, Inc.PMA supplementOct 21, 2026FDA
saypha ChiQP250021/S002
Croma-Pharma GmbHPMA supplementOct 8, 2026FDA
saypha ChiQP250021/S001
Croma-Pharma GmbHPMA supplementOct 7, 2026FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Prollenium Medical Technologies, Inc.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
138 Industrial Pkwy. N., Aurora, L4G 4C3

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records